CN100427068C - Kangai drip pill for treating tumour, hepatitis B and its preparation method - Google Patents
Kangai drip pill for treating tumour, hepatitis B and its preparation method Download PDFInfo
- Publication number
- CN100427068C CN100427068C CNB2005100634703A CN200510063470A CN100427068C CN 100427068 C CN100427068 C CN 100427068C CN B2005100634703 A CNB2005100634703 A CN B2005100634703A CN 200510063470 A CN200510063470 A CN 200510063470A CN 100427068 C CN100427068 C CN 100427068C
- Authority
- CN
- China
- Prior art keywords
- polyethylene glycol
- substrate
- kangai
- mixed
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The present invention discloses a medicinal composition which has the functions of vital energy benefit, health improvement and immunity enhancement and is used for treating primary liver cancer, lung cancer, rectum cancer, malignant lymphoma, gynaecologic malignant tumor, leucocyte hypofunction, leucocyte reduction caused by various reasons, chronic hepatitis B, etc. The present invention aims to overcome the defects of the existing oral medicinal liquid for treating the diseases and provide a Kangai oral dripping pill which has the advantages of high biological availability, rapidness for releasing medicine, rapidness for taking effect, few toxic and side effect, low cost for preparation and medical care, low price and suitability for household use. The Kangai dripping pill of the present invention is prepared from traditional Chinese medicine comprising milkvetch root, ginseng and ammothamnine as raw material and a medicinal carrier which is used as a substrate.
Description
Technical field
The present invention relates to a kind ofly have QI invigorating and set upright, the effect of enhancing human body immunity power, be used for the treatment of primary hepatocarcinoma, pulmonary carcinoma, rectal cancer, malignant lymphoma, gynecologic malignant tumor, and the low leukocyte counts that causes of a variety of causes and reduce disease, the pharmaceutical composition of diseases such as chronic hepatitis B is a kind of drug composition oral preparation that feedstock production forms with Chinese medicine astragalus, Radix Ginseng, kurarinone particularly.
Background technology
According to the Conair injection that the prescription that provides among the drug standard WS-11222 promulgated by the ministries or commissions of the Central Government of country (ZD-1222)-2002 and extraction process are prepared from, be a kind of primary hepatocarcinoma, pulmonary carcinoma, rectal cancer, malignant lymphoma, gynecologic malignant tumor of being used for the treatment of; Low leukocyte counts that a variety of causes causes and minimizing disease; The pure Chinese medicine of diseases such as chronic hepatitis B, through clinical verification for many years, steady quality, determined curative effect is the common drug that is used for the treatment of above-mentioned disease clinically with family.
Below be prescription and the extraction process that provides among the drug standard WS-11222 (ZD-1222) 2002:
Prescription: Radix Astragali 300g, Radix Ginseng 100g, kurarinone 10g;
Method for making: above three flavor medicines, Radix Ginseng 90% ethanol, reflux, extract, three times, each 2 hours, merge extractive liquid, is evaporated to relative density and is 1.10～1.20 clear paste, and was standby.The Radix Astragali decocts with water secondary, each 2 hours, filter merging filtrate, be evaporated to relative density and be 1.10～1.20 clear paste, merge with the Radix Ginseng clear paste, add ethanol and make and contain the alcohol amount and reach 75%, regulate pH value to 6～7 with sodium hydroxide, left standstill 12 hours, get supernatant, reclaim ethanol, be evaporated to relative density and be 1.10～1.15 clear paste; Add ethanol again and make and contain alcohol amount and reach 85%, regulate pH value to 6～7 with sodium hydroxide, leave standstill, filter, filtrate recycling ethanol adds the injection water to 400ml to there not being the alcohol flavor, regulates pH value to 6～7,100 ℃ sterilization 30 minutes, cold preservation, sucking filtration with sodium hydroxide.Regulate pH value to 6～7 with sodium hydroxide, it is an amount of to add active carbon, stirs evenly, and boils 15 minutes, filters filtrate for later use; Other gets kurarinone dissolving, regulates pH value to 6～7,100 ℃ sterilization 30 minutes with sodium hydroxide, cold preservation, and sucking filtration merges with the medicinal liquid that takes off behind the charcoal, and mixing adds the injection water to ormal weight, filters, fill, promptly.
Function cures mainly: QI invigorating is set upright, the enhancing human body immunity function.Be used for primary hepatocarcinoma, pulmonary carcinoma, rectal cancer, malignant lymphoma, gynecologic malignant tumor; Low leukocyte counts that a variety of causes causes and minimizing disease.The treatment of chronic hepatitis B.
Owing to be subjected to the influence of existing injection technology of preparing restriction and Chinese medicinal ingredients complexity, Chinese medicine injection often is easy to generate acute allergic reaction or untoward reaction, it is big also to exist operation easier simultaneously, the patient suffering is big, make and the medical treatment cost height, transportation stores inconvenience, and patient economy burden is heavy, shortcomings such as unsuitable family use.
In addition, owing to reasons such as technologies of preparing, the oral formulations of most drug exists all after taking that dissolve scattered time limit is long, dissolution is low, absorption is relatively poor, problem such as liver sausage first pass effect and bioavailability are lower, thereby influence the performance of drug effect, also directly affect therapeutic effect.Simultaneously, conventional peroral dosage form as tablet, capsule etc., because the technology of granulation is arranged, therefore can produce bigger dust pollution in preparation process, can staff's health be worked the mischief to a certain extent, also can cause certain pollution to environment simultaneously.Moreover, the complex manufacturing of conventional oral formulations, production cost is higher, thereby patient's drug cost is also improved thereupon, is unfavorable for improving the ability of seeking medical advice of extensive patients, also is unfavorable for improving the general health level of society.Therefore, be necessary to seek the peroral dosage form of better Flos Carthami medicine to satisfy the needs that clinical treatment and family use.
Summary of the invention
Purpose of the present invention, be to replenish existing be used for the treatment of primary hepatocarcinoma, pulmonary carcinoma, rectal cancer, malignant lymphoma, gynecologic malignant tumor, and the low leukocyte counts that causes of a variety of causes and reduce disease, the deficiency of the oral drug preparation of diseases such as chronic hepatitis B provides a kind of bioavailability height, release fast, quick produce effects, toxic and side effects is little, and manufacturing and medical treatment cost are low, low price, the oral Kangai drip pill that is suitable for family to use.Kangai drip pill involved in the present invention is a raw material with Chinese medicine astragalus, Radix Ginseng, kurarinone, is prepared from the pharmaceutically suitable carrier as substrate.
Be prepared by the following technical solutions, can obtain Kangai drip pill involved in the present invention:
[preparation method]
1. the preparation of drug extract: get Radix Astragali 300g, Radix Ginseng 100g, kurarinone 10g, more than three flavors, Radix Ginseng 90% ethanol, reflux, extract, 3 times, each 2 hours, merge extractive liquid, is evaporated to relative density and is 1.10～1.20 clear paste, and was standby; The Radix Astragali decocts with water 2 times, each 2 hours, filters, merging filtrate is evaporated to relative density and is 1.10～1.20 clear paste, merges with the Radix Ginseng clear paste, add ethanol and make and contain alcohol amount and reach 75%, regulate pH value to 6～7, left standstill 12 hours with sodium hydroxide, get supernatant, reclaim ethanol, be evaporated to relative density and be 1.10～1.15 clear paste, or continue to make drying under the same conditions, be ground into dry powder, promptly get drug extract thick paste or dry powder;
2. substrate: Polyethylene Glycol
(1000～20000), one or more the mixture in pharmaceutically suitable carrier such as polyoxyethylene stearate 40 esters, betacyclodextrin, poloxamer, carboxymethyl starch sodium, sodium lauryl sulphate, stearic acid, sodium stearate, glycerin gelatine, Lac;
3. proportioning: with g or kg is unit, by weight, and drug extract: substrate=1: 1～1: 9;
4. according to the given ratio of prescription, accurately take by weighing drug extract and substrate, be placed on heating while stirring in the heating container, standby until the fused solution that obtains containing drug extract and substrate and/or emulsion and/or suspension;
5. adopt homemade or general drop pill machine (as the TZDW-1 type drop pill machine of Changzheng Tianmin High Science ﹠ Technology Co., Ltd., Beijing's production), and the temperature control system of adjustment drop pill machine, make the water dropper temperature heating of drop pill machine and remain on (50～90) ℃, the temperature cooling of condensing agent also remains on (40～-5) ℃;
6. when treating that the temperature of condensing agent in dropping-pill machine head and the condensation column is stable respectively and reaching desired state of temperature, fused solution and/or the emulsion and/or the suspension that will contain drug extract and substrate, place in the water dropper jar of drop pill machine, splash in the condensing agent, condensing agent can be any one in liquid paraffin, methyl-silicone oil, the vegetable oil;
7. will shrink the drop pill taking-up of molding by the outlet of drop pill machine, remove the surface condensation agent, be drying to obtain.
[beneficial effect]
According to the Conair injection that the prescription that provides among the drug standard WS-11222 promulgated by the ministries or commissions of the Central Government of country (ZD-1222)-2002 and extraction process are prepared from, be a kind of primary hepatocarcinoma, pulmonary carcinoma, rectal cancer, malignant lymphoma, gynecologic malignant tumor of being used for the treatment of; Low leukocyte counts that a variety of causes causes and minimizing disease; The pure Chinese medicine of diseases such as chronic hepatitis B, through clinical verification for many years, steady quality, determined curative effect is the common drug that is used for the treatment of above-mentioned disease clinically with family.
Owing to be subjected to the influence of existing injection technology of preparing restriction and Chinese medicinal ingredients complexity, Chinese medicine injection often is easy to generate acute allergic reaction or untoward reaction, it is big also to exist operation easier simultaneously, the patient suffering is big, make and the medical treatment cost height, transportation stores inconvenience, and patient economy burden is heavy, shortcomings such as unsuitable family use.
The oral formulations of most drug, especially the oral formulations of Chinese medicine, exist all after taking that dissolve scattered time limit is long, dissolution is low, absorption is relatively poor, problem such as liver sausage first pass effect and bioavailability are lower, thereby influence the performance of drug effect, also directly affect therapeutic effect.In addition, conventional peroral dosage form as tablet, capsule etc., because the technology of granulation is arranged, therefore can produce bigger dust pollution in preparation process, can staff's health be worked the mischief to a certain extent, also can cause certain pollution to environment simultaneously.Moreover, the complex manufacturing of conventional oral formulations, production cost is higher, thereby patient's drug cost is also improved thereupon, is unfavorable for improving the ability of seeking medical advice of extensive patients, also is unfavorable for improving the general health level of society.
Kangai drip pill involved in the present invention is compared with the Conair injection, and following beneficial effect is arranged:
1. Kangai drip pill involved in the present invention; utilize surfactant to be substrate; make solid dispersion with the extractum or the dry powder that contain the Radix Astragali, Radix Ginseng, kurarinone active constituents of medicine; making medicine be molecule, colloid or microcrystalline state is scattered in the substrate; the total surface area of medicine increases, and substrate is hydrophilic, and medicine is had wetting action; can make that medicine is rapidly molten to loose into microgranule or solution, thereby make the dissolving of medicine and absorb and accelerate.Thereby improved bioavailability, brought into play efficient, quick-acting effects etc.
Compare with the administering mode of traditional oral formulations, exist essential distinction.Drop pill with the solid dispersion technology preparation can adopt oral and sublingual administration, and effective ingredient is fully contacted with mucomembranous surface, absorbs by mucomembranous epithelial cell, directly enters blood circulation.Owing to directly enter blood circulation without gastrointestinal tract and liver, avoided first pass effect effectively, also avoided gastrointestinal irritation, thereby it is rapid to have an onset, bioavailability height, characteristics such as side effect is little, and medication is convenient.
Chinese patent medicine injection series products is because of producing and basic research seriously lags behind, and the standardization issue of medicine never is resolved.The Chinese crude drug raw material itself is exactly a miscellaneous complex of chemical constituent, also there is not a kind of effective quality control method can reflect the quality and the difference thereof of product comprehensively, comprehensively, truly so far, and can carry out the quality control of production overall process effectively, cause the drug quality instability.The untoward reaction of Chinese medicine at present happens occasionally, but can't fundamentally understand fully to be due to which kind of composition, therefore can not in time make and deal with the aftermath of remedial measure targetedly, stay hidden danger for the hospital clinical medication.Injection manufacturing in addition, cost of transportation height use inconvenience, and this had both increased the weight of patient economy burden, have increased the misery of using again.Compare with Flos Carthami injection, the oral administration dripping pill agent has avoided medicine directly into blood, can reduce acute toxic and side effects and anaphylactoid generation effectively, and is safe and convenient to use, and effect is lasting, applied range; Manufacturing and medical treatment cost reduce greatly simultaneously, have effectively alleviated patient's financial burden, and have stored, transport, carry and use all more convenient.
2. Kangai drip pill involved in the present invention contacts promptly with saliva and to dissolve rapidly, and is absorbed by oral mucosa, and is not only rapid-action, and the influence of not taken food, and promptly all can containing take after meal ante cibum.
3. Kangai drip pill involved in the present invention mixes the extract that contains active constituents of medicine mutually with molten matrix, splashes in the not miscible condensed fluid and makes.Therefore, the stability of drug height, not facile hydrolysis, oxidation, and the operation be under liquid state, to carry out, no dust pollution is not subject to the influence of crystal formation, thereby has guaranteed the quality of medicine, has increased stability.
4. production technology, the equipment of preparation drop pill are simple, easy to operate, the automaticity height, and labor intensity is low, the production efficiency height.Workshop does not have dust simultaneously, helps labor protection and environmental protection yet.
5. the production cost of preparation drop pill is usually with about 50% of other oral formulations of kind, and compares with oral liquid, and the dosage of drop pill is accurate, thereby makes the patient take metering control easily.
The specific embodiment
Now with several groups of specific embodiments, be described further with regard to the preparation method of Kangai drip pill of the present invention.
[first group: the test of single-matrix]
1. raw material: it is standby to make the dry powder that contains Chinese medicine astragalus, Radix Ginseng, kurarinone active pharmaceutical ingredient in advance by preparation method 1;
2. substrate: Polyethylene Glycol
(1000,2000,4000,6000,8000,10000,20000), polyoxyethylene stearate 40 esters, betacyclodextrin, poloxamer, carboxymethyl starch sodium, sodium lauryl sulphate, stearic acid, sodium stearate, glycerin gelatine, Lac etc.;
3. proportioning: with g or kg is unit, by weight, and drug extract: substrate=1: 1～1: 9;
4. the process that provides according to [preparation method] 4～7 is prepared, and can obtain the Kangai drip pill of different size.
[result of the test]
Test 1: for observe drug extract and different substrates when 1: 1 the proportioning prepared Kangai drip pill in qualitative difference, according to 1: 1 ratio, with drug extract respectively with Polyethylene Glycol
1000, Polyethylene Glycol
2000, Polyethylene Glycol
4000, Polyethylene Glycol
6000, Polyethylene Glycol
8000, Polyethylene Glycol
10000, Polyethylene Glycol
20000, pharmaceutically suitable carrier such as polyoxyethylene stearate 40 esters, betacyclodextrin, poloxamer, carboxymethyl starch sodium, sodium lauryl sulphate, stearic acid, sodium stearate, glycerin gelatine, Lac matches, be prepared according to the step of stipulating in the preparation method, can obtain 16 pharmaceutical compositions experiments that contain drug extract and different substrates, and obtain 16 groups of different experimental results and see Table 1.
Test 2: for observe drug extract and different substrates when 1: 3 the proportioning prepared Kangai drip pill in qualitative difference, according to 1: 3 ratio, with drug extract respectively with Polyethylene Glycol
1000, Polyethylene Glycol
2000, Polyethylene Glycol
4000, Polyethylene Glycol
6000, Polyethylene Glycol
8000, Polyethylene Glycol
10000, Polyethylene Glycol
20000, pharmaceutically suitable carrier such as polyoxyethylene stearate 40 esters, betacyclodextrin, poloxamer, carboxymethyl starch sodium, sodium lauryl sulphate, stearic acid, sodium stearate, glycerin gelatine, Lac matches, be prepared according to the step of stipulating in the preparation method, can obtain 16 pharmaceutical compositions experiments that contain drug extract and different substrates, and obtain 16 groups of different experimental results and see Table 2.
Test 3: for observe drug extract and different substrates when 1: 9 the proportioning prepared Kangai drip pill in qualitative difference, according to 1: 9 ratio, with drug extract respectively with Polyethylene Glycol
1000, Polyethylene Glycol
2000, Polyethylene Glycol
4000, Polyethylene Glycol
6000, Polyethylene Glycol
8000, Polyethylene Glycol
10000, Polyethylene Glycol
20000, pharmaceutically suitable carrier such as polyoxyethylene stearate 40 esters, betacyclodextrin, poloxamer, carboxymethyl starch sodium, sodium lauryl sulphate, stearic acid, sodium stearate, glycerin gelatine, Lac matches, be prepared according to the step of stipulating in the preparation method, can obtain 16 pharmaceutical compositions experiments that contain drug extract and different substrates, and obtain 16 groups of different experimental results and see Table 3.
[second group: the test of mixed-matrix]
1. raw material: it is standby to make the dry powder that contains Chinese medicine astragalus, Radix Ginseng, kurarinone active pharmaceutical ingredient in advance by preparation method 1;
2. substrate:
2.1 Polyethylene Glycol---English name Macrogol,
2.2 polyoxyethylene stearate 40 esters---English name Polyoxyl (40) Stearate,
Molecular formula is with C
17H
35COO (CH
2CH
2O))
nH represents that n is about 40,
2.3 poloxamer---English name Poloxamer, polyoxyethylene poly-oxygen propylene aether,
Molecular formula HO (C
2H
4O)
a(C
3H
6O)
b(C
2H
4O)
cH,
The sodium salt of the starch carboxymethyl ester that 2.4 carboxymethyl starch sodium---English name Carboxymethylstach Sodium, starch generates with the monoxone effect under alkali condition,
2.5 betacyclodextrin---English name Betacyclodextrin, molecular formula C
6H
10O
5, this product is that ring dextrin glucosyl transferase acts on 7 glucoses that starch generates with α-1, the bonded cyclic oligosaccharide of 4-glycosidic bond;
3. proportioning: with g or kg is unit, by weight, and drug extract: substrate=1: 1～1: 9;
4. the process that provides according to [preparation method] 4～7 is prepared, and can obtain the Kangai drip pill of different size.
[result of the test]
Test 4: in order to observe the mass discrepancy of drug extract and mixed-matrix prepared Kangai drip pill when 1: 1 the proportioning, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 1 mixed evenly as mixed-matrix, according to 1: 1 ratio different with the 4 kinds respectively mixing matrix phases of drug extract are mixed again and make evenly, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that drug extract and mixed-matrix constituted, and obtain 4 groups of different experimental results and see Table 4.
Test 5: in order to observe the mass discrepancy of drug extract and mixed-matrix prepared Kangai drip pill when 1: 3 the proportioning, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 1 mixed evenly as mixed-matrix, according to 1: 3 ratio different with the 4 kinds respectively mixing matrix phases of drug extract are mixed again and make evenly, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that drug extract and mixed-matrix constituted, and obtain 4 groups of different experimental results and see Table 5.
Test 6: in order to observe the mass discrepancy of drug extract and mixed-matrix prepared Kangai drip pill when 1: 9 the proportioning, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 1 mixed evenly as mixed-matrix, according to 1: 9 ratio different with the 4 kinds respectively mixing matrix phases of drug extract are mixed again and make evenly, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that drug extract and mixed-matrix constituted, and obtain 4 groups of different experimental results and see Table 6.
Test 7: in order to observe the mass discrepancy of drug extract and mixed-matrix prepared Kangai drip pill when 1: 1 the proportioning, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 5 mixed evenly as mixed-matrix, according to 1: 1 ratio different with the 4 kinds respectively mixing matrix phases of drug extract are mixed again and make evenly, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that drug extract and mixed-matrix constituted, and obtain 4 groups of different experimental results and see Table 7.
Test 8: in order to observe the mass discrepancy of drug extract and mixed-matrix prepared Kangai drip pill when 1: 3 the proportioning, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 5 mixed evenly as mixed-matrix, according to 1: 3 ratio different with the 4 kinds respectively mixing matrix phases of drug extract are mixed again and make evenly, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that drug extract and mixed-matrix constituted, and obtain 4 groups of different experimental results and see Table 8.
Test 9: in order to observe the mass discrepancy of drug extract and mixed-matrix prepared Kangai drip pill when 1: 9 the proportioning, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 5 mixed evenly as mixed-matrix, according to 1: 9 ratio different with the 4 kinds respectively mixing matrix phases of drug extract are mixed again and make evenly, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that drug extract and mixed-matrix constituted, and obtain 4 groups of different experimental results and see Table 9.
Test 10: in order to observe the mass discrepancy of drug extract and mixed-matrix prepared Kangai drip pill when 1: 1 the proportioning, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 10 mixed evenly as mixed-matrix, according to 1: 1 ratio drug extract is mixed mutually with 4 kinds of different mixed-matrixes respectively again and make evenly, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that drug extract and mixed-matrix constituted, and obtain 4 groups of different experimental results and see Table 10.
Test 11: in order to observe the mass discrepancy of drug extract and mixed-matrix prepared Kangai drip pill when 1: 3 the proportioning, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 10 mixed evenly as mixed-matrix, according to 1: 3 ratio drug extract is mixed mutually with 4 kinds of different mixed-matrixes respectively again and make evenly, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that drug extract and mixed-matrix constituted, and obtain 4 groups of different experimental results and see Table 11.
Test 12: in order to observe the mass discrepancy of drug extract and mixed-matrix prepared Kangai drip pill when 1: 9 the proportioning, with polyoxyethylene stearate 40 esters, poloxamer, carboxymethyl starch sodium, 4 kinds of carriers such as betacyclodextrin respectively with Polyethylene Glycol with 1: 10 mixed evenly as mixed-matrix, according to 1: 9 ratio drug extract is mixed mutually with 4 kinds of different mixed-matrixes respectively again and make evenly, be prepared according to the step of stipulating in the preparation method, can obtain the experiment of 4 pharmaceutical compositions that drug extract and mixed-matrix constituted, and obtain 4 groups of different experimental results and see Table 12.
The group practices of table 1 drug extract and single-matrix (drug extract: substrate=1: 1)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyethylene Glycol 1000 | 50.0 | 63 | ＜30 | ＞10 | + |
| Polyethylene Glycol 2000 | 50.0 | 64 | ＜30 | ＞10 | + |
| Polyethylene Glycol 4000 | 50.0 | 74 | ＜30 | ＞10 | + |
| Polyethylene Glycol 6000 | 50.0 | 73 | ＜30 | ＞10 | ++ |
| Polyethylene Glycol 8000 | 50.0 | 74 | ＜30 | ＞10 | ++ |
| Polyethylene Glycol 10000 | 50.0 | 74 | ＜30 | ＞10 | ++ |
| Polyethylene Glycol 20000 | 50.0 | 79 | ＜30 | ＞10 | ++ |
| Polyoxyethylene stearate 40 esters | 50.0 | 81 | ＜30 | ＞10 | ++ |
| Betacyclodextrin | 50.0 | 74 | ＜30 | ＞10 | + |
| Poloxamer | 50.0 | 78 | ＜30 | ＞10 | +++ |
| Carboxymethyl starch sodium | 50.0 | 70 | ＜30 | ＞10 | + |
| Sodium lauryl sulphate | 50.0 | 73 | ＞30 | ＞10 | + |
| Stearic acid | 50.0 | 62 | ＞30 | ＞10 | ++ |
| Sodium stearate | 50.0 | 64 | ＞30 | ＞10 | ++ |
| Glycerin gelatine | 50.0 | 61 | ＞30 | ＞10 | + |
| Lac | 50.0 | 62 | ＞30 | ＞10 | + |
The group practices of table 2 drug extract and single-matrix (drug extract: substrate=1: 3)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyethylene Glycol 1000 | 25.0 | 67 | ＜30 | ＞10 | + |
| Polyethylene Glycol 2000 | 25.0 | 84 | ＜30 | ＞10 | ++ |
| Polyethylene Glycol 4000 | 25.0 | 86 | ＜30 | ＜10 | +++ |
| Polyethylene Glycol 6000 | 25.0 | 88 | ＜30 | ＜10 | +++ |
| Polyethylene Glycol 8000 | 25.0 | 92 | ＜30 | ＜10 | +++ |
| Polyethylene Glycol 10000 | 25.0 | 91 | ＜30 | ＜10 | +++ |
| Polyethylene Glycol 20000 | 25.0 | 90 | ＜30 | ＜10 | +++ |
| Polyoxyethylene stearate 40 esters | 25.0 | 90 | ＜30 | ＜10 | ++ |
| Betacyclodextrin | 25.0 | 82 | ＜30 | ＞10 | ++ |
| Poloxamer | 25.0 | 85 | ＜30 | ＜10 | +++ |
| Carboxymethyl starch sodium | 25.0 | 87 | ＜30 | ＞10 | +++ |
| Sodium lauryl sulphate | 25.0 | 76 | ＜30 | ＞10 | ++ |
| Stearic acid | 25.0 | 74 | ＞30 | ＞10 | +++ |
| Sodium stearate | 25.0 | 73 | ＞30 | ＞10 | +++ |
| Glycerin gelatine | 25.0 | 73 | ＞30 | ＞10 | +++ |
| Lac | 25.0 | 74 | ＞30 | ＞10 | +++ |
The group practices of table 3 drug extract and single-matrix (drug extract: substrate=1: 9)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyethylene Glycol 1000 | 10.0 | 76 | ＜30 | ＞10 | + |
| Polyethylene Glycol 2000 | 10.0 | 81 | ＜30 | ＞10 | ++ |
| Polyethylene Glycol 4000 | 10.0 | 86 | ＜30 | ＜10 | +++ |
| Polyethylene Glycol 6000 | 10.0 | 90 | ＜30 | ＜10 | +++ |
| Polyethylene Glycol 8000 | 10.0 | 87 | ＜30 | ＜10 | +++ |
| Polyethylene Glycol 10000 | 10.0 | 90 | ＜30 | ＜10 | +++ |
| Polyethylene Glycol 20000 | 10.0 | 92 | ＜30 | ＜10 | +++ |
| Polyoxyethylene stearate 40 esters | 10.0 | 91 | ＜30 | ＜10 | ++ |
| Betacyclodextrin | 10.0 | 84 | ＜30 | ＞10 | ++ |
| Poloxamer | 10.0 | 85 | ＜30 | ＜10 | +++ |
| Carboxymethyl starch sodium | 10.0 | 84 | ＜30 | ＞10 | +++ |
| Sodium lauryl sulphate | 10.0 | 78 | ＜30 | ＞10 | +++ |
| Stearic acid | 10.0 | 75 | ＞30 | ＞10 | +++ |
| Sodium stearate | 10.0 | 74 | ＞30 | ＞10 | +++ |
| Glycerin gelatine | 10.0 | 73 | ＞30 | ＞10 | +++ |
| Lac | 10.0 | 74 | ＞30 | ＞10 | +++ |
The group practices of table 4 drug extract and mixed-matrix (drug extract: mixed-matrix=1: 1)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 1 | 50 | 85 | ＜30 | ＞10 | ++ |
| Poloxamer: Polyethylene Glycol=1: 1 | 50 | 83 | ＜30 | ＞10 | ++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 1 | 50 | 82 | ＜30 | ＞10 | ++ |
| Betacyclodextrin: Polyethylene Glycol=1: 1 | 50 | 76 | ＜30 | ＞10 | + |
The group practices of table 5 drug extract and mixed-matrix (drug extract: mixed-matrix=1: 3)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 1 | 25 | 90 | ＜30 | ＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 1 | 25 | 87 | ＜30 | ＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 1 | 25 | 85 | ＜30 | ＞10 | ++ |
| Betacyclodextrin: Polyethylene Glycol=1: 1 | 25 | 85 | ＜30 | ＞10 | ++ |
The group practices of table 6 drug extract and mixed-matrix (drug extract: mixed-matrix=1: 9)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 1 | 10 | 91 | ＜30 | ＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 1 | 10 | 91 | ＜30 | ＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 1 | 10 | 88 | ＜30 | ＜10 | +++ |
| Betacyclodextrin: Polyethylene Glycol=1: 1 | 10 | 90 | ＜30 | ＞10 | +++ |
The group practices of table 7 drug extract and mixed-matrix (drug extract: mixed-matrix=1: 1)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 5 | 50 | 90 | ＜30 | ＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 5 | 50 | 91 | ＜30 | ＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 5 | 50 | 91 | ＜30 | ＜10 | +++ |
| Betacyclodextrin: Polyethylene Glycol=1: 5 | 50 | 90 | ＜30 | ＜10 | ++ |
The group practices of table 8 drug extract and mixed-matrix (drug extract: mixed-matrix=1: 3)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 5 | 25 | 92 | ＜30 | ＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 5 | 25 | 92 | ＜30 | ＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 5 | 25 | 91 | ＜30 | ＜10 | +++ |
| Betacyclodextrin: Polyethylene Glycol=1: 5 | 25 | 90 | ＜30 | ＜10 | +++ |
The group practices of table 9 drug extract and mixed-matrix (drug extract: mixed-matrix=1: 9)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 5 | 10 | 91 | ＜30 | ＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 5 | 10 | 91 | ＜30 | ＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 5 | 10 | 90 | ＜30 | ＜10 | +++ |
| Betacyclodextrin: Polyethylene Glycol=1: 5 | 10 | 91 | ＜30 | ＜10 | +++ |
The group practices of table 10 drug extract and mixed-matrix (drug extract: mixed-matrix=1: 1)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 10 | 50 | 92 | ＜30 | ＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 10 | 50 | 91 | ＜30 | ＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 10 | 50 | 87 | ＜30 | ＜10 | +++ |
| Betacyclodextrin: Polyethylene Glycol=1: 10 | 50 | 89 | ＜30 | ＞10 | +++ |
The group practices of table 11 drug extract and mixed-matrix (drug extract: mixed-matrix=1: 3)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 10 | 25 | 91 | ＜30 | ＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 10 | 25 | 91 | ＜30 | ＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 10 | 25 | 89 | ＜30 | ＜10 | +++ |
| Betacyclodextrin: Polyethylene Glycol=1: 10 | 25 | 89 | ＜30 | ＜10 | +++ |
The group practices of table 12 drug extract and mixed-matrix (drug extract: mixed-matrix=1: 9)
| The substrate title | Effective ingredient (%) | Rounding rate (%) | Dissolve scattered time limit (minute) | The ball method of double differences different (%) | Hardness |
| Polyoxyethylene stearate 40 esters: Polyethylene Glycol=1: 10 | 10 | 90 | ＜30 | ＜10 | +++ |
| Poloxamer: Polyethylene Glycol=1: 10 | 10 | 91 | ＜30 | ＜10 | +++ |
| Carboxymethyl starch sodium: Polyethylene Glycol=1: 10 | 10 | 91 | ＜30 | ＜10 | +++ |
| Betacyclodextrin: Polyethylene Glycol=1: 10 | 10 | 92 | ＜30 | ＜10 | +++ |
1. can be seen by the result in the table: when the ratio of drug extract and substrate was 1: 1, its rounding rate, the ball method of double differences was different and index such as hardness is all undesirable, and dissolve scattered time limit influenced not obvious.
2. when the ratio of drug extract and substrate is 1: 3, the rounding rate, the ball method of double differences is different and index such as hardness slightly all begins to enter preferable state.
3. when the ratio of drug extract and substrate is 1: 9, the rounding rate, the ball method of double differences is different and index such as hardness improves not obvious.
4. the general effect of composite interstitial substance is better than single-matrix.
5. the hardness method for expressing in the subordinate list adopts drop pill is placed on the glass plate, press...withes one's finger it, observes its metamorphosis."+" expression flicking promptly becomes
Claims (2)
1. a Kangai drip pill that is used for the treatment of tumor and hepatitis B is a raw material with Chinese medicine astragalus, Radix Ginseng, kurarinone, is prepared from the pharmaceutically suitable carrier as substrate, it is characterized in that:
(1) get Radix Astragali 300g, Radix Ginseng 100g, kurarinone 10g, more than three flavors, Radix Ginseng 90% ethanol, reflux, extract, 3 times, each 2 hours, merge extractive liquid, is evaporated to relative density and is 1.10～1.20 clear paste, and was standby; The Radix Astragali decocts with water 2 times, each 2 hours, filters, merging filtrate is evaporated to relative density and is 1.10～1.20 clear paste, merges with the Radix Ginseng clear paste, add ethanol and make and contain alcohol amount and reach 75%, regulate pH value to 6～7, left standstill 12 hours with sodium hydroxide, get supernatant, reclaim ethanol, be evaporated to relative density and be 1.10～1.15 clear paste, or continue to make drying under the same conditions, be ground into dry powder, promptly get the extract that contains pharmaceutically active ingredient in described three kinds, standby;
(2) described substrate is the mixture of Polyethylene Glycol and polyoxyethylene stearate 40 esters or carboxymethyl starch sodium, by weight, the mixed proportion of polyoxyethylene stearate 40 esters or carboxymethyl starch sodium and Polyethylene Glycol is 1: 5, describedly contains the extract of pharmaceutically active ingredient in three kinds and the ratio of substrate is 1: 3;
(3) according to aforementioned proportion, accurately take by weighing described extract and substrate, be placed in the heating container heating while stirring, standby until the fused solution that obtains containing described extract and substrate and/or emulsion and/or suspension;
(4) temperature control system of adjustment drop pill machine makes the water dropper heating of drop pill machine and maintains the temperature at 50 ℃～90 ℃, and the condensing agent cooling also maintains the temperature at 40 ℃～-5 ℃;
When (5) temperature for the treatment of dropping-pill machine head and condensing agent reaches described state respectively, will contain the fused solution of described extract and substrate and/or emulsion and/or suspension and place in the water dropper jar of drop pill machine, splash in the condensing agent, shrink molding promptly.
2. Kangai drip pill as claimed in claim 2 is characterized in that: described condensing agent be methyl-silicone oil or/and liquid paraffin or/and vegetable oil.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100634703A CN100427068C (en) | 2005-04-11 | 2005-04-11 | Kangai drip pill for treating tumour, hepatitis B and its preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100634703A CN100427068C (en) | 2005-04-11 | 2005-04-11 | Kangai drip pill for treating tumour, hepatitis B and its preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1686388A CN1686388A (en) | 2005-10-26 |
| CN100427068C true CN100427068C (en) | 2008-10-22 |
Family
ID=35304430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100634703A Active CN100427068C (en) | 2005-04-11 | 2005-04-11 | Kangai drip pill for treating tumour, hepatitis B and its preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100427068C (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1970001B (en) * | 2005-11-22 | 2011-07-20 | 山东轩竹医药科技有限公司 | Pharmaceutical composition comprising kurarinone, magnolia vine fruit and ginseng for treating hepatitis |
| CN102188598B (en) * | 2011-05-09 | 2012-08-22 | 江苏省中医院 | Chinese medicine formula for improving response of lamivudine in resisting hepatitis B virus |
-
2005
- 2005-04-11 CN CNB2005100634703A patent/CN100427068C/en active Active
Non-Patent Citations (4)
| Title |
|---|
| 中药药剂学. 范碧亭，380 381 383，上海科学技术出版社. 1997 * |
| 国家中成药标准汇编（肺系一分册）. 国家药品监督管理局，91， |
| 国家中成药标准汇编（肺系一分册）. 国家药品监督管理局，91，；国家药品监督管理局. 2002 * |
| 国家药品监督管理局. 2002 中药药剂学. 范碧亭，380 381 383，上海科学技术出版社. 1997 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1686388A (en) | 2005-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1322855C (en) | Oral drop pill in use for clearing away heat and toxic material and preparation method | |
| CN100382784C (en) | Danhong drip pill prepared from salvia root and carthamus and its preparation method | |
| CN100375614C (en) | Dripping pills with jaundice eliminating liver protecting functions and its preparation method | |
| CN100382786C (en) | Bastard feverfew throat clearing drip pill and its preparation method | |
| CN100427068C (en) | Kangai drip pill for treating tumour, hepatitis B and its preparation method | |
| CN100348170C (en) | Yitongshu drop pill for treating pain and its preparation method | |
| CN100364513C (en) | 'Gansu' dripping pills for treating hepatitis and its preparation method | |
| CN1315463C (en) | Guanxinning drip pill for treating heart disease and its preparation method | |
| CN100358506C (en) | Compound musk drip pill and its preparation method | |
| CN100348169C (en) | Saussurea involucrata drop pill and its preparation method | |
| CN100364505C (en) | Fengshining drop pill for treating rheumatism and its preparation method | |
| CN100367934C (en) | Yin-nourishing lung-heat clearing drop pills | |
| CN100358562C (en) | Tendril-leaved fritillary bulb loquat drop pills and preparation method thereof | |
| CN100453072C (en) | Isatis root drops and preparation thereof | |
| CN100358499C (en) | Xiaoaiping dripping pill for treating various cancers and its preparing method | |
| CN100427070C (en) | Dripping pills for treating all kinds of rhinitis and its preparation method | |
| CN100375630C (en) | Compound drop pills with flavescent sophora root and its preparation method | |
| CN100367937C (en) | Throat dripping pill for clearing away heat and toxic material and its preparing method | |
| CN1315464C (en) | Wild aconite drip pill for treating cancer pain and its preparation method | |
| CN1322854C (en) | Cold drop pills of mulberry and ginger in use for eliminating draft, clearing away heat, and preparing method | |
| CN100358496C (en) | 'Xingnaojing' dripping pills for treating cephalitis and hepatic coma and preparation process thereof | |
| CN1315472C (en) | Motherwort dropping pill and its preparing method | |
| CN100358500C (en) | Fleabane and earthworm dripping pill and its preparing method | |
| CN100398098C (en) | Ganoderma astragalus drip pill for treating heart spleen vacuity and its preparation method | |
| CN100528142C (en) | Aidi drops for treating cancers and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: HUBEI WUSHI PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: BEIJING ZHENGDA OASIS MEDICINE TECHNOLOGY CO., LTD. Effective date: 20110707 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100176 201, 2/F, TOWER B, INNOVATION BUILDING, NO. 12, HONGDA NORTH ROAD, ECONOMIC AND TECHNOLOGICAL DEVELOPMENT ZONE, BEIJING TO: 432600 NO. 137, BIYUN ROAD, ANLU CITY, XIAOGAN, HUBEI PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20110707 Address after: 432600 Hubei Province, Xiaogan Anlu Bi Yun Road No. 137 Patentee after: Hubei Wushi Pharmaceutical Co., Ltd. Address before: 100176 Beijing economic and Technological Development Zone Hongda North Road, building, No. two, block B, floor 201 Patentee before: Beijing Zhengda Oasis Medicine Technology Co., Ltd. |